Business · 30/11/2022Updated: 10/17/2026 · 1 min read
Mylan Institutional, Inc. Withdraws Approval of SULFAMYLON New Drug Application
Summary
Mylan Institutional, Inc., a subsidiary of Viatris, has voluntarily withdrawn its application for FDA approval of SULFAMYLON (Mafenide Acetate, USP) Powder for 5% Topical Solution, following a request to do so.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →